The plant has capacity to make 100 million aerosols cans a year according to Fareva, which said it plans to hire 80 to 100 people. The next phase of the project will see the firm invest a further $20m to set up four additional manufacturing lines.
Fareva bought the Richmond site from Pfizer in 2011. At present, it makes topical drugs, over the counter medicines - including the cough treatment Robitussin (guaifenesin) - and various consumer products for the North American market.